Patents by Inventor Michael Pfreundschuh

Michael Pfreundschuh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
    Patent number: 12227590
    Abstract: Disclosed are Synovial Sarcoma X breakpoint 2 binding molecules and methods for their use in the detection and treatment of cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: February 18, 2025
    Assignees: UNIVERSITAT DES SAARLANDES
    Inventors: Eric Yvon, Catherine Bollard, Stacey Van Pelt, Scott Raskin, Gerhard Held, Christine Sturm, Michael Pfreundschuh, deseased
  • METHODS AND COMPOSITION FOR A BINDING MOLECULE TARGETING CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN HLA-A*0201 CONTEXT
    Publication number: 20220185909
    Abstract: Disclosed are Synovial Sarcoma X breakpoint 2 binding molecules and methods for their use in the detection and treatment of cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 16, 2022
    Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE GEORGE WASHINGTON UNIVERSITY, UNIVERSITAT DES SAARLANDES
    Inventors: Eric YVON, Catherine BOLLARD, Stacey VAN PELT, Scott RASKIN, Gerhard HELD, Christine STURM, Michael PFREUNDSCHUH
  • Means and Methods for Treatment of B-Cell Malignancies
    Publication number: 20180169253
    Abstract: The present invention provides means and methods for diagnosing or treating B-cell malignancies. Novel conjugates for reverse targeting of B-cell receptors on malignant B cells are provided. The conjugates comprise a BCR antigen and a diagnostic or therapeutic agent. Also provided herein is a method for identifying patients disposed to respond favorably to treatment with a BCR antigen conjugate of the invention.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Inventor: Michael Pfreundschuh
  • PROGRANULIN AS MARKER FOR AUTOIMMUNE DISORDERS
    Publication number: 20150316548
    Abstract: The present invention provides for means and method for the detection and/or the quantification of anti-progranulin-autoantibodies in a biological sample of a subject. The present invention also provides for means and method for the detection and/or the quantification of hyper-phosphorylated progranulin in a biological sample of a subject. The present invention further provides for means and methods for the detection of an aberrant conversion pathway of progranulin into granulines in a biological sample of a subject. In fact, the presence of anti-progranulin-autoantibodies and/or hyper-phosphorylated progranulin and/or an aberrant conversion pathway may be indicative that the subject may be suffering from an autoimmune disorder.
    Type: Application
    Filed: November 27, 2013
    Publication date: November 5, 2015
    Inventors: Michael Pfreundschuh, Klaus-Dieter Preuss, Lorenz Thurner
  • Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies
    Patent number: 8679765
    Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: March 25, 2014
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Klaus-Dieter Preuss, Michael Pfreundschuh
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT AND NON-MALIGNANT GAMMOPATHIES
    Publication number: 20120014940
    Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.
    Type: Application
    Filed: January 22, 2010
    Publication date: January 19, 2012
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Klaus-Dieter Preuss, Michael Pfreundschuh
  • Isolated peptides which bind to MHC Class II molecules, and uses thereof
    Patent number: 7385044
    Abstract: Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4+ cells.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: June 10, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
    Patent number: 7270819
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: September 18, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Isolated peptides which bind to MHC class II molecules, and uses thereof
    Publication number: 20040214284
    Abstract: Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4+ cells.
    Type: Application
    Filed: May 21, 2004
    Publication date: October 28, 2004
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated peptides which bind to MHC class II molecules, and uses thereof
    Patent number: 6800730
    Abstract: Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4+ cells.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: October 5, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Tumor associated peptide and uses thereof
    Patent number: 6673350
    Abstract: The invention relates to a peptide with the sequence of RLLEFYLAM, methods for the use of the peptide, and antisera and monoclonal antibodies against the peptide. The peptide is derived from the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T lymphocytes.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: January 6, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
    Publication number: 20030185844
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Application
    Filed: June 21, 2002
    Publication date: October 2, 2003
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Tumor associated peptide and uses thereof
    Publication number: 20030175960
    Abstract: The invention relates to a peptide with the sequence of RLLEFYLAM, methods for the use of the peptide, and antisera and monoclonal antibodies against the peptide. The peptide is derived from the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T lymphocytes.
    Type: Application
    Filed: April 12, 2001
    Publication date: September 18, 2003
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
    Patent number: 6548064
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 15, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Method for identifying or isolating a molecule and molecules identified thereby
    Patent number: 6531280
    Abstract: The invention described methods for identifying a molecule of interest, as well as nucleic acid molecules which encode it, and binding partners for it. A cDNA library from a cell expressing the target is prepared, and expressed in host cells. Lysates of the host cells are screened with a sample, treated to remove interfering binding partners. The treatment involves contact of the sample to lysates of untransfected host cells, and host cells transfected or transformed with the same vector used to make the cDNA library. Also a part of the invention are antigens and cDNA identified using the methodology.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: March 11, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventor: Michael Pfreundschuh
  • Antibodies specific for SSX proteins
    Publication number: 20030023057
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Application
    Filed: October 11, 2001
    Publication date: January 30, 2003
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Regulatory elements from RP1 gene and uses thereof
    Publication number: 20020123092
    Abstract: The invention describes a promoter, isolated from the RP1 gene. The promoter is 10 times more active than known CMV promoters. Also described are nucleic acid molecules which are more extensive that the most active promoter described.
    Type: Application
    Filed: February 21, 2001
    Publication date: September 5, 2002
    Inventors: Andreas Wadle, Christoph Renner, Michael Pfreundschuh
  • Truncated forms of NY-ESO-1 protein
    Publication number: 20020010321
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Application
    Filed: December 29, 2000
    Publication date: January 24, 2002
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali O. Gure, Lloyd J. Old, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Elisabeth Stockert, Elke Jager, Knuth Alexander
  • SSX family proteins
    Patent number: 6339140
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: January 15, 2002
    Assignees: Ludwig Institute for Cancer Research, Cornell Medical Research Foundation, Memorial Sloan Kettering Cancer Center
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
    Patent number: 6338947
    Abstract: The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: January 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ugur Sahin, Özlem Türeci, Yao-Tseng Chen, Lloyd J. Old, Michael Pfreundschuh